Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ImmunoGen
Pharma
Apellis hit with yet another eye drug snub in Europe
Amid a parade of regulatory endorsements in Europe, Apellis’ ophthalmology prospect pegcetacoplan has been left in the cold once again.
Fraiser Kansteiner
Sep 20, 2024 10:06am
AbbVie's ImmunoGen buyout bears fruit with midstage trial win
Jun 6, 2024 11:22am
In less than 3 months, AbbVie closes $10.1B buyout of ImmunoGen
Feb 12, 2024 10:55am
Filing reveals how AbbVie's $10B ImmunoGen offer won out
Jan 2, 2024 3:33pm
With $10B deal, AbbVie doubles down on red-hot ADC field
Nov 30, 2023 9:16am
ImmunoGen's ADC Elahere delivers landmark ovarian cancer win
May 3, 2023 3:23pm
